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BACKGROUND: Barriers to randomised clinical trial (RCT) recruitment include failure to identify eligible patients, reluctance of staff to
approach them and attitudes of some health-care professionals and patients. As part of a larger UK prospective study examining the
communication and involvement in RCTs of 22 multidisciplinary teams in Wales, we also assessed the attitudes of patients they treat
towards trials.
METHODS: Out of 1146 patients attending outpatient departments who were approached, 1146 (93%) completed the seven-item
Attitudes to Randomised Trials Questionnaire (ARTQ), probing their general attitudes towards medical research and likely
participation in a hypothetical two-arm RCT.
RESULTS: Randomisation initially deterred many patients from endorsing a willingness to participate. However, if information about the
trial logic, voluntary nature and rights to withdraw were provided, together with further treatment details, 83% (886 out of 1066)
would potentially participate. Other variables associated with a positive inclination towards participation included previous trial
experience (Po0.01), male gender (Po0.01) and younger age, with patients X70 years less likely to consider trial entry (Po0.01).
CONCLUSION: The majority of patients were receptive to RCT participation. Many of those initially disinclined because of
randomisation would consider joining if given further details that form part of standard GCP consent guidelines. These data show the
importance and need for clear communication and information to encourage RCT participation. Evidence-based training courses are
available to assist with this.
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Worldwide, the number of potentially eligible patients recruited to
clinical trials is low, impeding accrual of the research evidence to
inform and improve clinical practice. The UK clinical research
networks aim to augment quality, relevance and focus of research
in the National Health Service (NHS) and, since its inception,
recruitment to cancer clinical trials has significantly improved.
Some trials recruit better than others, and the features
associated with this have been examined. Factors linked to good
and poor recruitments were explored in a cohort of 114
randomised clinical trials (RCTs) that had been recruiting
participants in the United Kingdom between 1994 and 2002
(McDonald et al, 2006). Almost a third of trials (31%) managed to
recruit their original target sample size, whereas a similar
proportion (31%) failed to do so. Even when investigators were
given a time extension, the proportion achieving targets improved
only slightly. Many trials (41%) were delayed in starting and
63% had problems at an early stage in the recruitment process.
The barriers found were similar to those identified in previous
studies: funding issues, changes in the hospital administrative
systems, fewer eligible patients than anticipated, problems
inherent to some trial types/methodology, (e.g., placebo control),
no treatment arms and the difficulties of describing randomisation
(McDonald et al, 2006; White et al, 2008a,b). Additionally, the
attitudes of both health professionals and patients towards RCTs
have a profound influence upon successful trial recruitment and
participation (Fallowfield et al, 1997, 1998; Ulrich et al, 2010).
The extra time involved in discussing a trial in busy NHS clinics
undoubtedly hampers recruitment, and some health-care profes-
sionals also introduce idiosyncratic eligibility criteria when
deciding which patients are even offered trials (Jenkins et al,
1999). Consequently, innovative workshops and educational
materials have been developed that have been shown to facilitate
health professionals’ discussions of trials (Jenkins et al, 2005).
Researchers from various disciplines have examined patients’
expectations and understanding about different aspects of the
consent procedure in an effort to identify ways to improve
the process (Burnet et al, 2004; Wright et al, 2004; Markman et al,
2006; Bergenmar et al, 2008). Interventions have tried to increase
patients’ knowledge about clinical trials, including the use of
audiovisual aids (Hutchison et al, 2007) or mass marketing
campaigns (Umutyan et al, 2008). Despite all these efforts, a better
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sunderstanding of patients’ attitudes might encourage health-care
professionals to approach more of their eligible patients and also
help refine the way they discuss the trial-relevant issues that are of
most importance to patients.
A small survey using the Attitudes to Randomised Trials
Questionnaire (ARTQ) (Fallowfield et al, 1998) conducted in
1996 suggested that most patients were willing to consider trial
participation. We administered the ARTQ to 41000 cancer
patients being treated by multidisciplinary teams (MDT) in Wales.
These data are a component of our large prospective study funded
by Cancer Research UK examining multidisciplinary team
members’ communication and involvement in clinical trials. The
main study examines different aspects of trial recruitment,
including (1) involvement of individual team members in clinical
trials, (2) clarity of the communication by health professionals
about clinical trials assessed by patients recruited to trials and
(3) the attitudes of both patients and clinicians towards RCTs.
The recruitment of patients to individual teams’ trial portfolios
were audited before the study intervention, that is, attendance at
customised MDT workshops. The attitudes of patients to RCTs
were collected for each team to provide an evidence-based
argument for them to consider approaching more patients about
trials. This paper reports those data.
MATERIALS AND METHODS
Questionnaire
The seven-item ARTQ (Fallowfield et al, 1998) measures a positive
or negative inclination towards (1) medical research in general;
(2) a personal willingness to be involved in research; and (3)
personal involvement in research involving randomisation. It is a
self-report questionnaire, available in English or Welsh. The first
three questions (see also Appendix 1) distinguish those who would
consider joining a clinical research study from those who are
uncertain or disinclined. Patients were asked to respond ‘Yes’, ‘No’
or ‘Do Not Know’ to these first three questions. Those who were
uncertain or disinclined about trial entry then read three
statements that described why the doctors want to do the study,
the patients’ right to withdraw at any time and the treatments and
side effects associated with the trial drugs. Participants responded
to each of the statements consecutively and then answered a
seventh and final question that asked if knowing the extra
information contained in the statements would now encourage
them to reconsider participation. Demographic details such as age,
sex, cancer site and whether or not the patient had previous trial
experience were also collected.
Sample
For each of the 22 MDTs participating in the larger communication
study, we gathered data from B50 patients per team attending
surgical and oncology clinics from May 2007 to November 2009.
The clinic staff helped identify suitable patients (namely, those not
about to receive bad news about a diagnosis or recurrence – we do
not have a record of how many participants fell into this category)
and researchers gave them information sheets about the study.
Consenting patients completed the ARTQ while they waited for
their clinical consultation, or at home and returned it in a prepaid
envelope. The study had full ethical approval (South East Wales
Local Research Ethics Committee Ref: 07/WSE03/17).
Statistical analysis
Analyses of the relationship between dichotomised (‘Yes’ vs ‘Do
Not Know’ and ‘No’) responses to individual questions and
individual or trial-specific characteristics (such as age and cancer
site) were conducted using logistic regression. The pattern of
answers for all patients was displayed in a parallel coordinates plot.
Additionally, patients were categorised into one of four ordered
categories, according to how they answered the crucial questions 3
and 7. Category 1 contained all individuals who answered ‘Yes’ to
question 3; categories 2–4 contained, respectively, the ‘Yes’,
‘Do Not Know’ and ‘No’ answers to question 7. This four-category
response was modelled using the continuation ratio approach to
ordinal data. Initial data exploration and all subsequent analyses
were carried out using the R statistical package (R Foundation for
Statistical Computing, Vienna, Austria).
RESULTS
Of the 1146 patients approached about the study, 1070 (93%) chose
to take part. Four of these did not complete the second page of
questions, leaving 1066 questionnaires suitable for analysis.
The sample contained more women (654) than men (412), but
the age distribution was comparable between sexes. More than half
of the women had breast cancer (336 out of 654). Table 1 shows the
characteristics in terms of age, sex, cancer type and previous trial
participation.
Table 2 shows the responses given by the 1066 patients to each
of the seven questions in the ARTQ. The first question (‘Do you
think patients should be asked to take part in medical research?’)
was widely supported, with 967 (91%) of patients answering ‘Yes’.
Approximately 70% of patients (781) stated that they would be
willing personally to participate in medical research (replying ‘Yes’
to ‘Would you be prepared to take part in a study comparing
different treatments?’), with the remainder largely undecided.
However, the ‘Yes’ figure fell to just over half (589) when asked
‘Would you be prepared to take part in a study where treatment
was chosen at random?’ (question 3). The 477 patients who
answered ‘No’ or ‘Do Not Know’ to question 3 completed questions
4–7. As further information was given, there was a gradual
increase in the proportion of favourable attitudes towards trial
participation (Table 2).
Concerns about randomisation are a notable feature of Figure 1,
a parallel coordinate plot of individuals’ responses to the seven
questions, divided for visual convenience into the four groups
previously mentioned (based on replies to questions 3 and 7). For
instance, in the top left panel, lines that begin at ‘Yes’, drop to ‘No’
before returning to ‘Yes’ represent patients who answered ‘Yes’,
Table 1 Patient characteristics, n (%)
Male
(n¼412)
Female
(n¼654)
Age group
20–35 7 (2%) 16 (2%)
36–50 29 (7%) 141 (22%)
51–65 172 (42%) 271 (42%)
65–80 183 (44%) 195 (30%)
80–85 20 (5%) 30 (4%)
Missing 1 1
Cancer site
Breast 0 (0%) 336 (51%)
Upper and lower gastrointestinal (GI) 159 (39%) 92 (14%)
Lung 49 (12%) 24 (4%)
Gynaecological 0 (0%) 113 (17%)
Urinary 96 (23%) 2 (0%)
Haematological 108 (26%) 87 (13%)
Previous trial experience
Yes 75 (18%) 135 (21%)
No 317 (77%) 496 (76%)
Unsure 20 (5%) 23 (3%)
Patients’ attitudes to trails
V Jenkins et al
1802
British Journal of Cancer (2010) 103(12), 1801–1807 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s‘No’ and ‘Yes’ to questions 1–3, respectively. Because such patients
were not required to answer questions 4–7, their lines end at this
point. The other three panels display the responses of all those who
did not answer ‘Yes’ to question 3, and hence continue into
answers to questions 4–7. Among the 297 patients who ultimately
answered ‘Yes’ to question 7 (top right panel), it is clear
from Figure 1 that the majority (172, 58%) had difficulties only
with the randomisation aspect of participation in medical research
(question 3).
We explored whether some of the variation in individual
response trajectories seen in Figure 1 could be explained by
demographic or disease-specific information. In univariate logistic
regression, men were significantly more likely to say ‘Yes’ to both
questions 2 and 3 than women were. The estimated odds ratios
were 1.52 and 1.51, respectively, with both P-values o0.01.
However, men were not significantly more likely to be encouraged
to consider trial entry by the statements and questions on the
second page of the questionnaire. In contrast, age was a strong
predictor of being more encouraged by the statements surround-
ing questions 4–7; both older (X80) and younger (p35) patients
undecided or disinclined at question 3 were less likely to agree to
participate (global P-values all o0.03). At question 3 itself, those
470 years of age were significantly less likely than their younger
counterparts to give a ‘Yes’ answer (P-value o0.01).
Unsurprisingly, those who had previous trial experience were
significantly more likely to agree to personal involvement and be
positively inclined towards future randomised trials (P-values
o0.01 for questions 1–3). In fact, of the 210 individuals with
trial experience, 162 (77%) said they would be willing to agree to
participate in a randomised trial again (question 3). Among the
48 who were disinclined or unsure, there was no consistent
indication that previous participation made them any more or less
likely to accept participation upon reaching question 7.
Like age, cancer site was significantly related to initial
inclination towards trials (P-values of 0.04 and o0.01 for
questions 2 and 3), but not obviously connected to the likelihood
Table 2 Responses to questions 1–7
Question Yes No
Do not
know
Q1. Do you think that patients should be asked to take part in medical research? 967 (91%) 29 (3%) 70 (6%)
Suppose that you were asked to take part in a research study comparing two treatments, both of which were
suitable for your illness.
Q2. Would you be prepared to take part in a study comparing different treatments? 781 (73%) 98 (9%) 187 (18%)
Usually, the only scientific way to compare one treatment with another is for the choice between the two to
be made randomly, rather like tossing a coin.
Q3. Would you be prepared to take part in a study where treatment was chosen at random? 589 (55%) 208 (20%) 269 (25%)
In a randomised study, a choice would be made between two treatments, either of which would be suitable
for you. Your doctor and experts in the field do not know for sure if one treatment is better than the other or
if they are both the same, that’s why they want to do the study.
Q4. Would knowing that encourage you to take part? 244 (51%) 102 (21%) 131 (28%)
In a random choice study, if the treatment you were receiving did not suit you for any reason, you could always
leave the study. Your doctor would then give you whatever other treatment might be appropriate for you.
Q5. Would that encourage you to take part? 305 (64%) 78 (16%) 94 (20%)
Before you agreed to enter a random choice study, the doctor would tell you all about the two treatments being
compared, including any side effects before you were allocated to one or the other.
Q6. Would that encourage you to take part? 282 (59%) 83 (17%) 112 (24%)
If you knew that the following were taken into account:
(a) that either treatment was completely suitable;
(b) that you could leave the study if the treatment did not suit you; and
(c) that there is plenty of information before the random choice was made
Q7. Would all these things together mean that you would change your mind and agree to take part? 297 (62%) 66 (14%) 114 (24%)
Yes
Do not know
Do not know
No
No
Q1 Q2 Q3 Q4 Q5 Q6 Q7
Question
Q1 Q2 Q3 Q4 Q5 Q6 Q7
Yes
A
n
s
w
e
r
Figure 1 Parallel coordinates plot. (A) Of the patients, those (589, 55%)
who were prepared to take part in a study where treatment was chosen at
random are shown. (B) Those 297 (28%) patients who, despite not being
prepared to take part in a study where treatment was chosen at random
(said ‘No’ to Q3), subsequently would agree to participate if they knew that
the following were taken into account: (1) that either treatment was
completely suitable, (2) that they could leave the study if the treatment did
not suit them, and (3) that there is plenty of information before the random
choice was made. (C) Of the patients, 114 (11%) who remained uncertain
about trial entry even with those factors in place. (D) Of the patients,
66 (6%) patients for whom the concept of a randomised trial is
unacceptable and would refuse trial entry despite all further information.
Patients’ attitudes to trails
V Jenkins et al
1803
British Journal of Cancer (2010) 103(12), 1801–1807 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sof being convinced (questions 4–7). The biggest individual effect
was seen in the gynaecological group, who were less likely to give a
‘Yes’ answer to question 3 (their estimated odds were 61% smaller
than the reference category of haematological cancers and
lymphoma).
Multivariate analysis
The division of patients according to their answers to questions 3
and 7 allows us to conduct a summary analysis of the variability in
patient attitudes. Results from modelling the ordinal outcome as a
function of age, sex, cancer site, previous trial participation and
study region are shown in the first set of columns of Table 3. As no
evidence that study region was an important indicator of attitude
was found, the model was refitted with these terms removed, as
shown in the second set of columns of Table 3. All other variables
retain strong statistical significance in global tests.
In particular, the odds of being in a group more favourably
inclined towards trials are nearly tripled if a patient has previously
participated in a trial, and are increased by 67% if the patient is
male. Lung and gynaecological cancer patients had 23 and
26% smaller odds of being more favourably inclined than those
with haematological cancer, whereas breast cancer patients had
23% higher odds.
To make this more concrete, consider four hypothetical patients.
All are aged between 50 and 65 years, and all have either
haematological malignancies or lymphoma. One is a woman not
having previously participated in a trial; based on our ordinal
model, her estimated probability of a ‘Yes’ answer (either at
question 3 or at question 7) is 78%. The other woman has
participated in an RCT before; her ‘Yes’ probability is 94%.
The other two patients are men: one is trial naive, and his chance
of a positive response is 88%. The final man has trial experience;
his probability is 97%.
Now consider two other patients, both female and both aged
between 50 and 65 years, neither of whom has previous trial
experience. If one is a breast cancer patient, her chance of agreeing
to participate is estimated by our model to be 82%. Should the
other have a gynaecological cancer, her model-based probability of
saying ‘Yes’ is just 70%.
DISCUSSION
This large survey revealed that the majority of patients with cancer
(83%) are willing to consider participation in clinical trials. Just
over half the patients approached were happy to enter even with
the difficult concept of randomisation explained only minimally.
Of the 45% (477 out of 1066) of patients who expressed unease at
the prospect of randomisation, two-thirds (62%; 297 out of 477)
changed their minds and would consider joining when provided
with further types of information that form part of the standard
informed consent discussion described in good clinical practice
guidelines. Specifically, they were told the logic for the trial and all
treatments were suitable, they had the right to withdraw from the
study and that they would be provided with information about the
treatments and possible side effects. The results accord closely with
the 1996 study, which involved a smaller cohort of patients with
breast and urological cancer attending University College London
and Royal Marsden hospitals (Fallowfield et al, 1998).
The finding that men were less likely than women to be
dissuaded by the introduction of randomisation was unexpected.
This result might reflect the willingness of men to take part in
seemingly riskier activities; explanation of the scientific rationale
for randomisation was not provided unless patients were
undecided or said ‘No’. Deciding to participate in a randomised
trial has an element of risk in that the participant would not know
which treatment s/he would receive until after consenting to the
RCT. Data show that women as a group of any age are more risk
averse than men (Gustafson, 1998) and women find risky
situations more stressful (Lighthall et al, 2009). More recently,
Han et al (2009), in a survey involving 44000 members of the US
public, reported that aversion to the uncertainty of risk informa-
tion was associated with older age, lower socioeconomic education
and female sex. One limitation of our study is that we did not
gather any education or employment data; results such as the
gender differences may possibly be explained in terms of other
demographic variables.
Patients’ preference for and understanding of the term rando-
misation has been widely studied (Featherstone and Donovan,
1998, 2002). In one study, patients expressed a preference for
descriptions of randomisation that gave more of the rationale, and
a dislike for analogies, especially ‘coin-tossing’ (Jenkins et al,
2002). The use of the coin-tossing analogy to describe randomisa-
tion in the current study may have further discouraged patients to
consider participation in the hypothetical two-treatment arm trial.
The fact that given additional information, so many of those
who initially dissented or who were uncertain would be likely to
consider RCTs demonstrates the importance of ensuring that these
issues are not omitted from trial discussions. It is too easy to
assume that the patient information sheets cover these areas
satisfactorily. Apart from the fact that few patients read these and
that reading them is highly correlated with education (Hietanen
et al, 2000), many information sheets are written at too high a
reading level (Paasche-Orlow et al, 2003) and are convoluted in
style (Knapp et al, 2009).
In contrast, it is important to note that 6% (66 out of 1066) of
patients were not prepared to consider entry into a randomised
trial despite additional information, and a further 11% (114 out of
1066) remained uncertain. Data collected by the South Wales
WCRN (Wales Cancer Research Network) regional centres for the
period 2009–2010 revealed that 39% of patients (627 out of 1589)
declined to participate in an RCT (WCRN, personal communica-
tion). These figures might be interpreted as showing that a greater
number of patients in routine clinical practice than in hypothetical
surveys will refuse RCTs, but establishing reasons for accepting or
declining trial entry is important. A limitation of the results from
our study is that patients were asked to consider a hypothetical
scenario about trial entry, but not only does the ARTQ
differentiate those patients who do and do not feel comfortable
Table 3 Ordinal regression table
OR 95% CI P-value OR 95% CI P-value
(Intercept) 1.30 (0.61, 2.89) 0.51 1.24 (0.60, 2.68) 0.58
CohortordinalX2 1.58 (1.25, 1.98) o0.01 1.57 (1.25, 1.98) o0.01
CohortordinalX3 1.82 (1.30, 2.56) o0.01 1.81 (1.30, 2.56) o0.01
Cohort (global) o0.01 o0.01
Agegp(35,50) 0.92 (0.42, 1.95) 0.83 0.93 (0.42, 1.97) 0.85
Agegp(50,65) 0.71 (0.33, 1.47) 0.36 0.72 (0.33, 1.48) 0.38
Agegp(65,80) 0.63 (0.29, 1.30) 0.22 0.64 (0.29, 1.32) 0.23
Agegp(80,95) 0.44 (0.19, 1.00) 0.05 0.45 (0.19, 1.01) 0.06
Agegp (global) o0.01 o0.01
Sexm 1.67 (1.25, 2.23) o0.01 1.67 (1.25, 2.23) o0.01
Cancersitebreast 1.18 (0.83, 1.66) 0.35 1.23 (0.89, 1.72) 0.21
Cancersitecolo+uppergi 0.97 (0.69, 1.35) 0.84 0.95 (0.69, 1.32) 0.77
Cancersitegynae 0.75 (0.50, 1.12) 0.16 0.74 (0.50, 1.09) 0.13
Cancersitelung 0.75 (0.48, 1.17) 0.20 0.77 (0.50, 1.19) 0.24
Cancersiteurology 0.83 (0.53, 1.29) 0.40 0.83 (0.54, 1.29) 0.41
Cancersite (global) 0.10 0.04
Prevpartnot sure 0.62 (0.39, 0.99) 0.05 0.61 (0.39, 0.97) 0.04
Prevpartyes 2.81 (2.07, 3.87) o0.01 2.78 (2.05, 3.80) o0.01
Prevpart (global) o0.01 o0.01
Regionse 0.91 (0.71, 1.17) 0.45
Regionsw 1.04 (0.76, 1.41) 0.82
Region (global) 0.58
Abbreviations: CI¼confidence interval; OR¼odds ratio.
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swith the concept of randomisation, but also in a previous study it
reliably predicted with 80% accuracy those patients who would go
on to participate in a clinical trial (Fleissig et al, 2001).
Our results show that 480% of cancer patients might well be
prepared to participate in randomised controlled trials. However,
just under half of those will be initially put off by the concept of
randomisation and will require further explanation to enable them
to accept the concept of a trial and feel comfortable about consent.
Among those who refuse trial entry in routine oncology practice,
there is a group for whom such research is unacceptable. Different
types of trial design, such as placebo control and multi arm,
anxieties about side effects or the extra effort that some trials
require may all be disincentives.
Although we should be aware of possible coercion in some trials
in which very high (490%) consent levels have been achieved,
such figures could of course be because of attractive features of the
trial. These include drugs or devices without the likelihood of
severe adverse events, trials that have little extra effort or burdens,
or the trial may be the only way in which patients can access a
novel drug or procedure.
Our results contribute to an evidence base that patients’
attitudes are not the cause of low recruitment to trials. A
significant minority (B20%) have deeply held concerns and
should not be coerced into unwilling participation in cancer or
other randomised trials. However, the message for investigators
and research staff is that most patients are willing to consider trial
participation, although many require in-depth discussion to
resolve fears raised by the concept of randomisation.
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